The c.-292C>T promoter polymorphism increases reticulocyte-type 15-lipoxygenase-1 activity and could be atheroprotective

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 4, 2007, Pages 487-492

  Wittwer, Jonas ^a   Bayer, Mathias ^b   Mosandl, Armin ^b   Muntwyler, Jörg ^c   Hersberger, Martin ^a,d  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

15 lipoxygenase (15 LOX); Inflammation; Lipoxin; Polymorphism; PU.1; Reticulocyte type 15 lipoxygenase 1 (ALOX15); SFPI1; SPI1; Transcription factor

Indexed keywords

15 HYDROXYICOSATETRAENOIC ACID; ARACHIDONATE 15 LIPOXYGENASE; LIPOXIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BINDING SITE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; PROMOTER REGION; RETICULOCYTE;

ARACHIDONATE 15-LIPOXYGENASE; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY ARTERIOSCLEROSIS; CYTOSINE; FEMALE; HUMANS; MALE; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; THYMINE;

EID: 34247357016     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.103     Document Type: Article

References (22)

1. Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 1999; 274:23679-82.
2. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, et al. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999;400:378-82.
3. Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2002;2:787-95.
4. Chiang N, Arita M, Serhan CN. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids 2005;73:163-77.
5. Kuhn H, Walther M, Kuban RJ. Mammalian arachidonate 15-lipoxygenases structure, function, and biological implications. Prostaglandins Other Lipid Mediat 2002;68-69:263-90.
6. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z Kardiol 2001;90(Suppl 3):125-32.
7. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004;45:993-1007.
8. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-478.
9. Wittwer J, Marti-Jaun J, Hersberger M. Functional polymorphism in ALOX15 results in increased allele-specific transcription in macrophages through binding of the transcription factor SPI1. Hum Mutat 2006;27:387.
10. Wittwer J, Marti-Jaun J, Hersberger M. Functional polymorphism in ALOX15 results in increased allele-specific transcription in macrophages through binding of the transcription factor SPI1. Hum Mutat 2006;27:78-87.
11. Hersberger M, Muntwyler J, Funke H, Marti-Jaun J, Schulte H, Assmann G, et al. The CAG repeat polymorphism in the androgen receptor gene is associated with HDL-cholesterol but not with coronary atherosclerosis or myocardial infarction. Clin Chem 2005;51:1110-5.
12. Muntwyler J, Marti-Jaun J, Luscher TF, Hanseler E, Hersberger M. No evidence for involvement of the human inducible nitric oxide synthase gene in susceptibility to coronary artery disease. Clin Chem Lab Med 2005;43:253-5.
13. Vanderhoek JY, Bryant RW, Bailey JM. Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy-5,8,11,13-eicosatetraenoic acid. J Biol Chem 1980;255:10064-6.
14. Smith RJ, Justen JM, Nidy EG, Sam LM, Bleasdale JE. Transmembrane signaling in human polymorphonuclear neutrophils: 15(S)-hydroxy-(5Z,8Z,11Z,13E)- eicosatetraenoic acid modulates receptor agonist-triggered cell activation. Proc Natl Acad Sci USA 1993;90:7270-4.
15. Takata S, Papayianni A, Matsubara M, Jimenez W, Pronovost PH, Brady HR. 15-Hydroxyeicosatetraenoic acid inhibits neutrophil migration across cytokine-activated endothelium. Am J Pathol 1994;145:541-9.
16. Colgan SP, Serhan CN, Parkos CA, Delp-Archer C, Madara JL. Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J Clin Invest 1993;92:75-82.
17. Shen J, Kuhn H, Petho-Schramm A, Chan L. Transgenic rabbits with the integrated human 15-lipoxygenase gene driven by a lysozyme promoter: macrophage-specific expression and variable positional specificity of the transgenic enzyme. FASEB J 1995;9:1623-31.
18. Shen J, Herderick E, Cornhill JF, Zsigmond E, Kim HS, Kuhn H, et al. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest 1996;98:2201-8.
19. Serhan CN, Jain A, Marleau S, Clish C, Kantarci A, Behbehani B, et al. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol 2003;171:6856-65.
20. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apoE-deficient mice. J Clin Invest 1999;103:1597-604.
21. Huo Y, Zhao L, Hyman MC, Shashkin P, Harry BL, Burcin T, et al. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;110:2024-31.
22. Harats D, Shaish A, George J, Mulkins M, Kurihara H, Levkovitz H, et al. Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2000;20:2100-5.